Atul Pande's most recent trade in Immunovant Inc was a trade of 1,500 Common Stock done at an average price of $38.0 . Disclosure was reported to the exchange on June 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 38.01 per share. | 26 Jun 2026 | 1,500 | 116,731 (0%) | 0% | 38.0 | 57,015 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.43 per share. | 26 Jun 2026 | 1,500 | 118,231 (0%) | 0% | 8.4 | 12,645 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 1,500 | 68,181 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 15 Jun 2026 | 1,500 | 116,731 (0%) | 0% | 34.0 | 51,030 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.43 per share. | 15 Jun 2026 | 1,500 | 118,231 (0%) | 0% | 8.4 | 12,645 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 1,500 | 69,681 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2026 | 6,000 | 270,252 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 20 May 2026 | 6,000 | 116,731 (0%) | 0% | 32 | 192,000 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.43 per share. | 20 May 2026 | 6,000 | 122,731 (0%) | 0% | 8.4 | 50,580 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 13,880 | 116,731 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 7,061 | 7,061 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 16,188 | 102,851 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,600 | 7,600 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Pande Atul | Director | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 02 Dec 2024 | 7,750 | 86,663 (0%) | 0% | 28.5 | 221,185 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 11,255 | 94,413 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 4,690 | 4,690 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 40.46 per share. | 01 Dec 2023 | 4,847 | 83,158 (0%) | 0% | 40.5 | 196,110 | Common Stock |
| Immunovant Inc | Pande Atul | Director | Sale of securities on an exchange or to another person at price $ 38.80 per share. | 01 Dec 2023 | 4,129 | 91,379 (0%) | 0% | 38.8 | 160,205 | Common Stock |
| Immunovant Inc | Pande Atul | Director | Sale of securities on an exchange or to another person at price $ 39.82 per share. | 01 Dec 2023 | 3,374 | 88,005 (0%) | 0% | 39.8 | 134,353 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 1,904 | 1,904 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 990 | 990 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 16,260 | 16,260 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 12,523 | 95,508 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Atul Pande | Director | Purchase of securities on an exchange or from another person at price $ 5.60 per share. | 30 Sep 2022 | 15,000 | 20,000 (0%) | 0% | 5.6 | 84,000 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 31,668 | 31,668 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 21,059 | 82,985 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 5,000 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 2,500 | 0 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Feb 2022 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 110.80 per share. | 01 Feb 2022 | 2,500 | 0 (0%) | 0% | 110.8 | 277,000 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 71,492 | 208,973 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Atul Pande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 21,726 | 61,926 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 2,500 | 2,500 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 03 Jan 2022 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 130.44 per share. | 03 Jan 2022 | 2,500 | 0 (0%) | 0% | 130.4 | 326,100 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 127.73 per share. | 01 Dec 2021 | 2,500 | 0 (0%) | 0% | 127.7 | 319,325 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2021 | 2,500 | 5,000 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Dec 2021 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 136.67 per share. | 01 Nov 2021 | 2,500 | 0 (0%) | 0% | 136.7 | 341,675 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,500 | 7,500 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Nov 2021 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 2,500 | 10,000 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 120.72 per share. | 01 Oct 2021 | 2,500 | 0 (0%) | 0% | 120.7 | 301,800 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Oct 2021 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 117.82 per share. | 01 Sep 2021 | 2,500 | 0 (0%) | 0% | 117.8 | 294,550 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,500 | 12,500 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 01 Sep 2021 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Immunovant Inc | Atul Pande | Director | Purchase of securities on an exchange or from another person at price $ 7.98 per share. | 13 Aug 2021 | 5,000 | 45,200 (0%) | 0% | 8.0 | 39,900 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 02 Aug 2021 | 2,500 | 2,500 (0%) | 0% | 16 | 40,000 | Common Stock |
| Karuna Therapeutics Inc | Atul Pande | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2021 | 2,500 | 15,000 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Atul Pande | Director | Sale of securities on an exchange or to another person at price $ 114.17 per share. | 02 Aug 2021 | 2,500 | 0 (0%) | 0% | 114.2 | 285,425 | Common Stock |